RxDoctor Payments Data

Ramesh Gowda, MD

Interventional Cardiology · New York, NYNPI 1073589636

Payments from drug & device makers

$131,376in general payments, 2019–2025

Across 1,114 payments — averaging $117.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$63K
  • Bard Peripheral Vascular, Inc.$19K
  • Inari Medical, Inc.$9K
  • Boston Scientific$7K
  • Penumbra, Inc.$4K
  • Angiodynamics, Inc.$4K
  • plus $26K from 42 others

What the payments were for

  • Consulting fees$15,18512%
  • Speaking & faculty fees$43,25033%
  • Travel & lodging$12,1759%
  • Food & beverage$58,52145%
  • Education$5450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$131,376 in reported general payments places this provider in the 80th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$129,853
Medicare patients
312
Services billed
1,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban239$250,774
EntrestoSacubitril/Valsartan125$139,189
XareltoRivaroxaban109$102,537
Repatha SureclickEvolocumab81$89,798
BrilintaTicagrelor48$53,304
JardianceEmpagliflozin41$41,750
FarxigaDapagliflozin Propanediol31$39,455
VascepaIcosapent Ethyl52$29,785
VerquvoVericiguat14$12,955
Praluent PenAlirocumab12$10,307
Rosuvastatin Calcium533$7,052
ClopidogrelClopidogrel Bisulfate621$6,666
Atorvastatin Calcium563$6,594
Ezetimibe243$6,159
Metoprolol Succinate422$5,645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$201$250,774239 claims
NovartisEntresto$499$139,189125 claims
Johnson & JohnsonXarelto$137$102,537109 claims
AstraZenecaBrilinta, Farxiga$171$92,75979 claims
Boehringer IngelheimJardiance$1,054$41,75041 claims
MerckVerquvo$363$12,95514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →